Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection

Journal of Viral Hepatitis

Volumn 21, Issue 1, 2014, Pages 42-52

  Mihm, U ^a   Welker, M W ^a   Teuber, G ^b   Wedemeyer, H ^c   Berg, T ^d   Sarrazin, C ^a   Bohm S ^d   Alshuth, U ^e   Herrmann, E ^f   Zeuzem, S ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Medizinisches Versorgungszentrum   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e ROCHE INNOVATION CENTER MUNICH   (Germany)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

IL28B genotype; ribavirin monotherapy; ribavirin priming; viral kinetics

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DETERIORATION; DRUG EFFECT; DRUG SAFETY; FEMALE; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS; TREATMENT RESPONSE;

IL28B GENOTYPE; RIBAVIRIN MONOTHERAPY; RIBAVIRIN PRIMING; VIRAL KINETICS;

ADULT; AGED; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; PLACEBOS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84890552666     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12124     Document Type: Article

References (31)

1. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
2. McHutchison JG, Manns MP, Muir AJ, et al,. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
3. Brok J, Gluud LL, Gluud C,. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev 2005; CD005527.
4. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
5. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
6. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R,. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-279. (Pubitemid 40165370)
7. Jacobson IM, Brown RS Jr, Freilich B, et al,. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-981. (Pubitemid 350144761)
8. McHutchison JG, Manns M, Patel K, et al,. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
9. Loustaud-Ratti V, Alain S, Rousseau A, et al,. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47: 1453-1461. (Pubitemid 351702729)
10. Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, Francois C,. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther 2010; 15: 687-695.
11. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ,. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53: 32-41.
12. Feld JJ, Lutchman GA, Heller T, et al,. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139: 154-162.
13. Feld JJ, Nanda S, Huang Y, et al,. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563. (Pubitemid 350155537)
14. Pawlotsky JM, Dahari H, Neumann AU, et al,. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703-714. (Pubitemid 38298318)
15. Zeuzem S,. Standardtherapie der akuten und chronischen Hepatitis C. Z Gastroenterol 2004; 42: 714-719. (Pubitemid 39166161)
16. Sarrazin C, Berg T, Ross RS, et al,. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289-351.
17. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
18. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS,. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-924. (Pubitemid 40037156)
19. Murphy AA, Herrmann E, Osinusi AO, et al,. Twice-weekly pegylated interferon-alpha-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS 2011; 25: 1179-1187.
20. Fischer J, Bohm S, Scholz M, et al,. Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection. Hepatology 2012; 55: 1700-1710.
21. Shou WZ, Bu HZ, Addison T, Jiang X, Naidong W,. Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum. J Pharm Biomed Anal 2002; 29: 83-94. (Pubitemid 34621273)
22. Fan C, Zhang D, Zhang CH,. On Sample Size of the Kruskal-Wallis-Test with Application to a Mouse Peritoneal Cavity Study. Biometrics 2011; 67: 213-224.
23. Asahina Y, Izumi N, Enomoto N, et al,. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005; 43: 623-629. (Pubitemid 41253229)
24. Merli M, Giannelli V, Gentili F, et al,. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study. Antivir Ther 2011; 16: 879-885.
25. Furusyo N, Kubo N, Toyoda K, et al,. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. Antiviral Res 2005; 67: 46-54. (Pubitemid 40798918)
26. Ogawa K, Hige S, Nakanishi M, et al,. Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C. Antivir Ther 2009; 14: 513-522.
27. Rotman Y, Noureddin M, Feld JJ, et al,. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2013; doi: 10.1136/gutjnl-2012-303852.
28. Zeuzem S, Asselah T, Angus P, et al,. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047-2055.
29. Zeuzem S, Buggisch P, Agarwal K, et al,. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55: 749-758.
30. Chu TW, Kulkarni R, Gane EJ, et al,. Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C. Gastroenterology 2012; 142: 790-795.
31. Neumann AU, Lam NP, Dahari H, et al,. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107. (Pubitemid 28471138)